Cypex is pleased to share that in July of this year, we were acquired by BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development. 

This is the perfect pairing, both for our team and customers. We view BioIVT as a like-minded partner; we share the same commitment to supplying high-quality products and a passion for ensuring that our customers have the best products for their research. We’re thrilled that our customers will gain access to BioIVT’s hepatocytes and other hepatic products and benefit from its well-established global biospecimen network and robust supply chain

BioIVT Chief Executive Office, Richard Haigh, commented: “We are delighted that the Cypex team is joining BioIVT, bringing with them not only their market-leading products, but also their in vitro drug metabolism technology expertise. The acquisition of Cypex enhances BioIVT’s product portfolio, ensuring that we continue to meet all our biopharmaceutical customers’ research requirements for their entire R&D pipeline.”

Since our first recombinant CYP enzyme was introduced in early 2000, we’ve built an extensive product range. This is an exciting new phase for Cypex and we want to thank everyone who has supported us over the years and look forward to sharing our future endeavours as BioIVT with you.